Arabic Arabic English English French French German German
dark

MEI Pharma and Kyowa Kirin receive Orphan Drug Designation for Zandelisib for the Treatment of Follicular Lymphoma

MEI Pharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) granted orphan-drug designation (ODD) to zandelisib for the treatment of follicular lymphoma. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Zosano Pharma Reports Third Quarter 2021 Financial Results

Next Post

Secarna Pharmaceuticals and Achilles Therapeutics Sign Research, Option and License Agreement to Develop Optimized T Cell Therapies

Related Posts
Total
0
Share